On 9 June 2026, the US Food and Drug Administration added bemotrizinol to the list of active ingredients permitted in over-the-counter sunscreens, according to the agency’s news release. It is the first new active ingredient added to the OTC sunscreen monograph since the late 1990s, which is where the widely repeated phrase “first time in 20 years” comes from.
The ingredient is not new to chemistry, to dermatology, or to most of the world. Bemotrizinol has been sold in sunscreens across Europe and many other markets for years, often under the trade name Tinosorb S. What changed in June was not the molecule. It was the American regulatory status of the molecule.
That distinction matters, because the announcement is easy to read as a scientific advance and is better understood as an administrative one.
What the FDA actually did
The agency issued a final order amending its OTC monograph for sunscreen drug products to include bemotrizinol at concentrations up to 6 per cent. The request came from DSM Nutritional Products LLC, which submitted what the system calls an OTC monograph order request. The FDA proposed the change on 12 December 2025, took public comment until 26 January 2026, and finalised the order roughly seven months after the proposal.
In its release the FDA states that bemotrizinol provides protection against both ultraviolet A and ultraviolet B radiation and shows low absorption through the skin into the body. The agency considers it generally recognised as safe and effective, in the regulatory language “GRASE”, for use by adults and children six months of age and older.
This is the first ingredient cleared under the streamlined monograph process created by the CARES Act of 2020, which was intended to give the FDA a faster route to revise OTC drug rules than the decades-long rulemaking it replaced.
Why UVA coverage is the part worth understanding
The reason a single ingredient draws attention is the kind of protection it offers. Sunscreen filters are not interchangeable. Some absorb mainly UVB, the shorter-wavelength radiation most associated with sunburn. Fewer absorb strongly across the UVA range, the longer wavelengths linked to skin ageing and to deeper skin damage. Bemotrizinol absorbs across both bands, which is why formulators value it: it can do work that otherwise requires combining several filters.
The practical effect, on the available evidence, is that US formulators gain a tool that chemists elsewhere have been building around for a long time. The claim worth resisting is that American sunscreens were unprotective before this. They were not. The narrower and more accurate point is that the US filter list has been shorter than those of the European Union, Japan, and Australia, and this addition closes part of that gap.
Reading the announcement carefully
The FDA release is also a political document, and it is worth separating the regulatory facts from the framing around them. The decision is presented as a deliverable of the current administration’s Make America Healthy Again strategy, and is quoted as such by Health and Human Services Secretary Robert F. Kennedy Jr, who said bemotrizinol “has been used safely in Europe for decades” and that the action “will increase competition and consumer confidence”. Those are the words of the department announcing the change, not an independent assessment of it.
The underlying regulatory claims are narrower and more checkable: one ingredient, one concentration ceiling, one monograph, cleared through one new statutory process. The breadth of “consumer confidence” is an aspiration attached to the decision rather than a measured outcome of it.
It is also worth being precise about what a clearance is not. Adding an ingredient to the permitted list does not put a product on a shelf. Manufacturers still have to formulate, test, and bring finished sunscreens to market under the monograph’s conditions. The timeline from this order to a bottle a shopper can buy is a commercial question the FDA’s action does not answer.
What to watch next
Three things will show whether this is a one-off or the start of a pattern. The first is how quickly US brands actually reformulate around bemotrizinol, and at what price. The second is whether other long-pending filters that are common abroad follow it through the CARES Act process, or whether this remains a single clearance. The third is the durability of the seven-month timeline the agency is highlighting: a fast review on one well-documented ingredient is not yet evidence of a faster system. The final order in the Federal Register is the document to track as those questions resolve.
